On the whole, anti-hypertensive drugs correlated with death from prostate cancer before diagnosis (HR, 1.21; 95% CI, 1.04–1.4) and after diagnosis (HR, 1.2; 95% CI, 1.02–1.41).Angiotensin II type 1 receptor blockers were associated with improved survival (HR, 0.81; 95% CI, 0.67–0.99), while diuretics were associated with an increased risk of mortality (HR, 1.25; 95% CI, 1.05–1.49). The gene discussed is AGTR1; the disease is Familial prostate cancer.